The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phage Therapy in Clinical Practice: Treatment of Human Infections
Abstract
Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the world's imagination--see, especially, Arrowsmith by Sinclair Lewis (1925)--and which today is the primary motivator of the field. Nonetheless, though the first human phage therapy took place in the 1920s, by the 1940s the field, was in steep decline despite early promise. The causes were at least three-fold: insufficient understanding among researchers of basic phage biology; over exuberance, which led, along with ignorance, to carelessness; and the advent of antibiotics, an easier to handle as well as highly powerful category of antibacterials. The decline in phage therapy was neither uniform nor complete, especially in the former Soviet Republic of Georgia, where phage therapy traditions and practice continue to this day. In this review we strive toward three goals: 1. To provide an overview of the potential of phage therapy as a means of treating or preventing human diseases; 2. To explore the phage therapy state of the art as currently practiced by physicians in various pockets of phage therapy activity around the world, including in terms of potential commercialization; and 3. To avert a recapitulation of phage therapy's early decline by outlining good practices in phage therapy practice, experimentation, and, ultimately, commercialization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Church, D., Elsayed, S., Reid, O., Winston, B., & Lindsay, R. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.403-434.2006 · Cited by 1,876
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationPolicing stabilizes construction of social niches in primates
Flack, J. C., Girvan, M., de Waal, F. B. M., & Krakauer, D. C. (2006) · Nature · doi:10.1038/nature04326 · Cited by 718
Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy
Bruttin, A., & Brüssow, H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2874-2878.2005 · Cited by 563
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Self-citationPhage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Self-citationMarkoishvili, K., Tsitlanadze, G., Katsarava, R., Glenn, J., Morris Jr., M. D., & Sulakvelidze, A. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01451.x · Cited by 243
Bacteriophage penetration in vertebrates
Dabrowska, K., Switala-Jelen, K., Opolski, A., Weber-Dabrowska, B., & Gorski, A. (2005) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2004.02422.x · Cited by 240
Górski, A., Ważna, E., DÄ browska, B.-W., DÄ browska, K., ÅwitaÅa-JeleÅ, K., & MiÄdzybrodzki, R. (2006) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2006.00044.x · Cited by 227
Bacteriophage Therapy of Bacterial Infections: An Update of our Institute’s Experience
Weber-Dąbrowska, B., Mulczyk, M., & Górski, A. (2001) · Inflammation · doi:10.1007/978-94-015-9702-9_15 · Cited by 199
Bacteriophage Therapy in Humans
Sulakvelidze, A., & Kutter, E. (2004) · Bacteriophages · doi:10.1201/9780203491751.ch14 · Cited by 170
Self-citationJikia, D., Chkhaidze, N., Imedashvili, E., Mgaloblishvili, I., Tsitlanadze, G., Katsarava, R. D., Morris, J. G., & Sulakvelidze, A. (2005) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01600.x · Cited by 160
The potential role of endogenous bacteriophages in controlling invading pathogens
Górski, A., & Weber-Dabrowska, B. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4403-6 · Cited by 159
Goodridge, L. D. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725348 · Cited by 155
Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa
Soothill, J. S. (1994) · Burns · doi:10.1016/0305-4179(94)90184-8 · Cited by 145
Eaton, M. D., & Bayne‐Jones, S. (1934) · JAMA · doi:10.1001/jama.1934.72750490003007 · Cited by 138
Félix d`Herelle and the Origins of Molecular Biology
Summers, W. C. (1999) · Cited by 138
Bacteriophage therapy for the treatment of infections.
Górski, A., Międzybrodzki, R., Borysowski, J., et al. (2009) · PubMed · Cited by 129
Dubos, R. J., Straus, J. H., & Pierce, C. (1943) · The Journal of Experimental Medicine · doi:10.1084/jem.78.3.161 · Cited by 123
Studies on bacteriophage penetration in patients subjected to phage therapy.
Weber‐Dąbrowska, B., Dabrowski, M., & Šlopek, S. (1987) · PubMed · Cited by 105
Bacteriophages and Transplantation Tolerance
Górski, A., Kniotek, M., Perkowska‐Ptasińska, A., Mróz, A., Przerwa, A., Gorczyca, W., Dąbrowska, K., Weber‐Dąbrowska, B., & Nowaczyk, M. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.12.073 · Cited by 100
Preparation of endotoxin-free bacteriophages.
Boratyński, J., Syper, D., Weber‐Dąbrowska, B., Łusiak-Szelachowska, M., Poźniak, G., & Górski, A. (2004) · PubMed · Cited by 99
European Regulatory Conundrum of Phage Therapy
Verbeken, G., Vos, D. D., Vaneechoutte, M., Merabishvili, M., Zizi, M., & Pirnay, J. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.485 · Cited by 94
New insights into the possible role of bacteriophages in host defense and disease
Górski, A., Dąbrowska, K., Świtała-Jeleń, K., Nowaczyk, M., Weber‐Dąbrowska, B., Boratyński, J., Wietrzyk, J., & Opolski, A. (2003) · Medical Immunology · doi:10.1186/1476-9433-2-2 · Cited by 90
Krueger, A. P., & SCRIBNER, E. J. (1941) · JAMA · doi:10.1001/jama.1941.62820190016010 · Cited by 74
Dąbrowska, K., Opolski, A., Wietrzyk, J., Świtała-Jeleń, K., Boratyński, J., Nasulewicz‐Goldeman, A., Lipinska, L., Chybicka, A., Kujawa, M., Zabel, M., et al. (2004) · PubMed · Cited by 68
Międzybrodzki, R., Fortuna, W., Weber‐Dąbrowska, B., & Górski, A. (2009) · Clinical and Experimental Medicine · doi:10.1007/s10238-009-0044-2 · Cited by 67
Weber‐Dąbrowska, B., Zimecki, M., & Mulczyk, M. (2000) · PubMed · Cited by 65
C.G. Paine and the earliest surviving clinical records of penicillin therapy
Wainwright, M., & Swan, H. (1986) · Medical History · doi:10.1017/s0025727300045026 · Cited by 55
Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models.
Dąbrowska, K., Opolski, A., Wietrzyk, J., Świtała-Jeleń, K., Godlewska, J., Boratyński, J., Syper, D., Weber‐Dąbrowska, B., & Górski, A. (2004) · PubMed · Cited by 50
Bacterial viruses against viruses pathogenic for man?
Międzybrodzki, R., Fortuna, W., Weber‐Dąbrowska, B., & Górski, A. (2005) · Virus Research · doi:10.1016/j.virusres.2005.01.009 · Cited by 43
Pajtasz‐Piasecka, E., Rossowska, J., Duś, D., Weber‐Dąbrowska, B., Zabłocka, A., & Górski, A. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.11.004 · Cited by 43
New insights into the possible role of bacteriophages in transplantation
Górski, A., Nowaczyk, M., Weber‐Dąbrowska, B., Kniotek, M., Boratyński, J., Ahmed, A., Dąbrowska, K., Wierzbicki, P., Świtała-Jeleń, K., & Opolski, A. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00811-x · Cited by 27
Taddonio, T. E., Thomson, P. D., Tait, M. J., Prasad, J. K., & Feller, I. (1988) · Burns · doi:10.1016/0305-4179(88)90035-6 · Cited by 23
Cited by
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Self-citationPhage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 998
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Self-citationPhage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Self-citationJault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Metadata
- Authors
- Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 69-86
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2117840807
- Cited by
- 670
- References
- 36
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.